171 related articles for article (PubMed ID: 2935338)
1. Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity.
Turner MW; Seymour ND; Kazatchkine MD; Mowbray JF
Clin Exp Immunol; 1985 Nov; 62(2):427-34. PubMed ID: 2935338
[TBL] [Abstract][Full Text] [Related]
2. A study of C3b deposition on yeast surfaces by sera of known opsonic potential.
Turner MW; Mowbray JF; Roberton DR
Clin Exp Immunol; 1981 Nov; 46(2):412-9. PubMed ID: 7039889
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect.
Turner MW; Seymour ND; Kazatchkine MD; Mowbray JF
Clin Exp Immunol; 1985 Nov; 62(2):435-41. PubMed ID: 3910314
[TBL] [Abstract][Full Text] [Related]
4. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
5. Opsonization of yeast cells with equine iC3b, C3b, and IgG.
Gröndahl G; Johannisson A; Jensen-Waern M; Nilsson Ekdahl K
Vet Immunol Immunopathol; 2001 Aug; 80(3-4):209-23. PubMed ID: 11457475
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of C3b/C3bi opsonization and chemiluminescence with selected yeasts and bacteria using sera of different opsonic potential.
Turner MW; Grant C; Seymour ND; Harvey B; Levinsky RJ
Immunology; 1986 May; 58(1):111-5. PubMed ID: 3519441
[TBL] [Abstract][Full Text] [Related]
7. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
Zhang MX; Klein B
Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
[TBL] [Abstract][Full Text] [Related]
8. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
10. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
11. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
Garred P; Mollnes TE; Lea T; Fischer E
Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
[TBL] [Abstract][Full Text] [Related]
13. The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations.
Super M; Levinsky RJ; Turner MW
Clin Exp Immunol; 1990 Feb; 79(2):144-50. PubMed ID: 2311294
[TBL] [Abstract][Full Text] [Related]
14. Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement.
Ezekowitz RA; Sim RB; MacPherson GG; Gordon S
J Clin Invest; 1985 Dec; 76(6):2368-76. PubMed ID: 2934410
[TBL] [Abstract][Full Text] [Related]
15. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
16. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
Melamed J; Medicus RG; Arnaout MA; Colten HR
J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
[TBL] [Abstract][Full Text] [Related]
17. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
[TBL] [Abstract][Full Text] [Related]
18. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
19. Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase.
Carlo JR; Spitznagel JK; Studer EJ; Conrad DH; Ruddy S
Immunology; 1981 Oct; 44(2):381-91. PubMed ID: 7028603
[TBL] [Abstract][Full Text] [Related]
20. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
